[EN] NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES<br/>[FR] NOUVEAUX BENZOIMIDAZOLES EN TANT QU'INHIBITEURS SÉLECTIFS DE L'INDOLÉAMINE 2, 3-DIOXYGÉNASES
申请人:BEIGENE LTD
公开号:WO2019101188A1
公开(公告)日:2019-05-31
Disclosed herein are novel benzoimidazoles and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy. In particular, disclosed herein are certain novel benzoimidazoles that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.
QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS
申请人:PIERRE FABRE MEDICAMENT
公开号:US20160229834A1
公开(公告)日:2016-08-11
The present invention relates to compounds of the following formula (I): and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.
Synthesis and in vitro antitubercular activity of a series of quinoline derivatives
作者:Marcus V.N. de Souza、Karla C. Pais、Carlos R. Kaiser、Mônica A. Peralta、Marcelle de L. Ferreira、Maria C.S. Lourenço
DOI:10.1016/j.bmc.2009.01.013
日期:2009.2
A series of 33 quinolinederivatives have been synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Compounds 5e and 5f exhibited a significant activity at 6.25 and 3.12 μg/mL, respectively, when compared with first line